China's Foreign Ministry is protesting a U.S. bill that targets several Chinese biotech companies and their US subsidiaries. The Biosecure Act seeks to ban a group of five biotechnology companies with Chinese ties from working with anyone who receives federal money. Einar Tangen, senior fellow at the Taihe Institute and Chairman of Asia Narratives, says China needs to prepare for more such actions. He adds that it's a "hot and cold" strategy pushed by populists politics, part of America's victimization narrative.